Investigation of the etiology and tumor biology of renal cell carcinoma
| Jakobsson, Rasmus | ||
| 2026-03-30T08:24:12Z | ||
| 2026-03-30 | ||
| Background: Approximately 1,300 people are diagnosed with renal cell carcinoma (RCC) in Sweden each year. The aim of this thesis was to study predisposing factors for RCC development and aspects of its tumor biology connected to cellular uptake mechanisms. Furthermore, to describe novel RCC subtypes and explore potential therapeutic implications. Materials and methods: Fresh-frozen tumor samples, histological material including tissue microarrays, primary cell cultures, and cell lines were analyzed. Whole-genome sequencing, RNA sequencing, public RCC datasets, and epidemiological registry data were evaluated. Selected metabolic features were assessed by mass spectrometry (RP-LC-MS/MS) and ToF-SIMS. Results: Paper I showed that expression of SARS-CoV-2 entry factors ACE2, TMPRSS2, and NRP1 were retained by papillary and clear cell RCC. Primary cancer cells became infected and displayed distinct virus-induced cytopathogenic effects. Paper II demonstrated that RCC risk was doubled if a parent or sibling was diagnosed with RCC. The median age at diagnosis was similar to that of sporadic RCC, with higher risk for women. Paper III showed that genomic clustering of RCC cases from The Cancer Genome Atlas (TCGA), together with TMA analyses, indicated morphological and molecular overlap between the indolent RCC with fibromyomatous stroma (RCCFMS) and clear cell papillary renal cell tumor (CCPRCT). Paper IV demonstrated that the characteristic yellow-orange colour of clear cell RCC stems from accumulation of β-carotene, potentially mediated by increased uptake via SCARB1. Enzymes involved in β-carotene and retinol metabolism were detected in tumor tissue. Conclusion: Selective targeting of RCC may be possible using virus-based delivery strategies. Familial RCC appears to be relatively common and has not yet received a complete genetic explanation. The benign clear cell tumor CCPRCT may represent part of the same spectrum of indolent clear cell tumors as RCCFMS, associated with epigenetic silencing of VHL. Increased β-carotene uptake in clear cell RCC may represent a potential target for diagnostic and therapeutic applications. | ||
| 0026-04-24 | ||
| Fredagen den 24 april 2026, kl. 9.00, Hörsal Arvid Carlsson, Academicum, Medicinaregatan 3, Göteborg | ||
| Institute of Biomedicine. Department of Laboratory Medicine | ||
| SA | ||
| rasmus.jakobsson@vgregion.se | ||
| University of Gothenburg. Sahlgrenska Academy | eng | |
| 978-91-8115-669-0 (tryck) | ||
| 978-91-8115-670-6 (PDF) | ||
| https://hdl.handle.net/2077/90407 | ||
| eng | ||
| Choong OK, Jakobsson R, Bergdahl AG, Brunet S, Kärmander A, Waldenström J, Arvidsson Y, Altiparmak G, Nilsson JA, Karlsson J, Nyström K, Johansson. ME. SARS-CoV-2 replicates and displays oncolytic properties in clear cell and papillary renal cell carcinoma. PLoS One. 2023 Jan. http://doi.org/10.1371/journal.pone.0279578 | ||
| Jakobsson RG, Nasic S, Bratt O, Johansson ME, Grenabo Bergdahl A. Family History and Risk of Renal Cell Carcinoma: A National Multiregister Case-Control Study. J Urol. 2024 Jan. http://doi.org/10.1097/JU.0000000000003765 | ||
| Jakobsson R, Lindström M, Arvidsson Y, Johansson I, Nilsson JA, Karlsson J, Johansson ME. Clear cell papillary renal cell tumour and renal cell carcinoma with fibromyomatous stroma share overlapping molecular and immunohistochemical features. Manuscript. | ||
| Jakobsson R, Bergh PO, Christianson J, Johansson S, Lundgren J, Peters B, Malmberg P, Johansson ME. Why So Orange? The Role of β-Carotene in the colour of Clear Cell Renal Cell Carcinoma. Manuscript. | ||
| Renal cell carcinoma | ||
| SARS-CoV-2 | ||
| Hereditary | ||
| RCCFMS | ||
| β-carotene | ||
| Investigation of the etiology and tumor biology of renal cell carcinoma | ||
| text | eng | |
| Doctor of Philosophy (Medicine) | ||
| Doctoral thesis | eng |
Files
License bundle
1 - 1 of 1
Loading...
- Name:
- license.txt
- Size:
- 4.68 KB
- Format:
- Item-specific license agreed upon to submission
- Description: